Lifecare traces its origins to a discovery about osmotic pressure, and it operates through a set of specialised subsidiaries rather than one integrated unit, with one of them already selling a medical device commercially. The company started out as a venture developing a patented artificial pancreas, and its sensor work builds on the finding that tracking osmotic pressure can accurately reflect glucose levels. It runs operational development through subsidiaries, and the RemovAid implant-removal device is sold to health clinics in Norway.
Sencell uses osmotic pressure-based sensors to provide continuous glucose monitoring for people with diabetes, with a sensor that lasts a minimum of six months and measures glucose levels in real time, against devices that typically have a sensor lifespan of 7 to 15 days. Lifecare Veterinary adapts the Sencell technology to the veterinary market, targeting animals such as dogs and cats. Most approved CGM devices are attached to the skin with a small needle that penetrates the skin.